Glycomimetics
Crescent Biopharma, formerly known as GlycoMimetics, is a late clinical-stage biotechnology company specializing in glycobiology-based therapies aimed at treating cancers and inflammatory diseases. The company's lead candidate, uproleselan, is in pivotal Phase 3 development for relapsed refractory acute myeloid leukemia (AML) and has garnered Breakthrough Therapy and Fast Track designations from the U.S. FDA.
Recognized as a pioneer in glycobiology, Crescent Biopharma leverages its proprietary chemistry platform and expertise in carbohydrate functions to develop innovative medicines intended to enhance patient outcomes. The company emphasizes the importance of collaborative efforts with leading academic institutions, governmental organizations, and pharmaceutical biotechnology companies to advance its research initiatives.
Generated from the website